Dr. Roybal is an Assistant Professor in the Department of Microbiology and Immunology at the University of California, San Francisco. He received his doctorate in Immunology from UT Southwestern Medical Center and was a Jane Coffin Childs Memorial Fund Postdoctoral Fellow in the laboratory of Wendell A. Lim at UCSF and the Howard Hughes Medical Institute.
He is currently a member of the Parker Institute for Cancer Immunotherapy, the Helen Diller Family Comprehensive Cancer Center, and an inaugural Chan Zuckerberg Biohub Investigator. He is also the Deputy Director of the UCSF Center for Synthetic Immunology recently funded by the Cancer Moonshot Initiative. He was awarded the Sartorius and Science Magazine Prize for Regenerative Medicine and Cell Therapy and the NIH New Innovator Award in 2018.
The Roybal lab harnesses the tools of Synthetic Biology and Immunology to control and customize immune cell therapeutics for cancer and autoimmunity. His body of work was foundational to the next-generation immune cell therapy company, Cell Design Labs, where he was a founding scientist. Cell Design Labs was acquired by Gilead at the end of 2017. He was also instrumental in developing universal CAR T cell technology in collaboration with Xyphos Biosciences, which was acquired by Astellas at the end of 2019. He has now co-founded Arsenal Biosciences, which focuses on building cellular therapies for solid tumors with a combination of cutting-edge synthetic biology and gene editing technologies.
As Global Head of R&D at the Janssen Pharmaceutical Companies of Johnson & Johnson, Mathai’s mission is to focus the energy of the best research and development teams in the world at the intersection of profound unmet medical need and actionable breakthroughs in science and technology to make medicines of unequivocal benefit for humanity. The team works across a wide range of therapeutic areas and biological pathways. Janssen’s approach to medicines is patient-focused, agnostic to both source of the idea and the treatment modality. The team is invested deeply in data sciences in every aspect of R&D. Janssen R&D has fueled the growth of Janssen to be the largest pharmaceutical company in the United States, and the fourth largest in the world.
Prior to Janssen, Mathai was SVP at Merck Research Laboratories, and with his team he initiated numerous new programs and progressed eight into early clinical development. At Theravance, a company he co-founded in 1997 based on his work at Harvard University, his talented team nominated 31 development candidates and created five approved products.
Mathai has more than 150 peer-reviewed publications and patents and serves on various boards and advisory committees. He received his M.D. from Harvard Medical School/Massachusetts Institute of Technology (HST program) and his Ph.D. in Chemistry from Harvard University’s Department of Chemistry.
Todd Park is Co-Founder and Executive Chairman of Devoted Health, a company focused on dramatically improving health care for seniors. Prior to Devoted Health, Todd served as White House technology advisor based in Silicon Valley until January 2017, a role in which he focused on bringing top technology talent and best practices into government to improve service delivery, national defense, public engagement, and more. Prior to this role, Todd served from March 2012 to August 2014 as U.S. Chief Technology Officer in the White House Office of Science and Technology Policy and, in that position, served as an Assistant to the President. Todd joined the Obama Administration in August 2009 as Chief Technology Officer of the U.S. Department of Health and Human Services (HHS), where he functioned as an “entrepreneur-in-residence,” helping HHS harness the power of data, technology, and innovation to improve the health of the nation. For his work at HHS, Todd was named one of Fast Company’s “100 Most Creative People in Business” in 2010.
Prior to his work in government, Todd co-founded Athenahealth in 1997 and co-led its development over more than a decade into a leading provider of cloud-based software and services for physicians and health care practitioners. He also co-founded Castlight Health, an innovative online health benefits platform company, in 2008, and has served as a senior advisor to Ashoka, a global incubator of social entrepreneurs, where he helped start a venture to bring affordable telehealth, drugs, diagnostics, and clean water to rural India.
Todd graduated magna cum laude and Phi Beta Kappa from Harvard College with an A.B. in Economics. He currently serves on the boards of New America and the Biden Cancer Initiative and on the Obama Foundation’s Digital & Technology Council. Todd was elected a Fellow of the National Academy of Public Administration in 2017 and is a member of the 2017 Class of Henry Crown Fellows within the Aspen Global Leadership Network at the Aspen Institute.
John joined the Venrock family in 1998, shortly after co-founding Illumina (Nasdaq: ILMN) and convincing Bryan to make it his first investment. John was Illumina’s first CEO, and most recently its COO. After leaving Illumina, John co-founded Ariosa (a Venrock portfolio company), serving as its Executive Chairman until its acquisition by Roche. In addition, John was the Chairman at Sequenta until its acquisition by Adaptive (Nasdaq: ADPT). Currently, John is Chairman at the following Venrock portfolio companies: 10x Genomics (Nasdaq: TXG), Inscripta, and Element Biosciences, and also serves on the Board of Directors for Encoded Therapeutics. He is also the Chairman at Fabric Genomics.
John has a BS and a DVM from the University of California, Davis and an MBA from the University of Los Angeles.
DJ Patil joined Venrock in 2017 as an Advisor to the firm. He has held a variety of roles in Academia, Industry, and Government, most recently he was appointed by President Obama to be the first U.S. Chief Data Scientist where his efforts led to the establishment of nearly 40 Chief Data Officer roles across the Federal government. He also established new health care programs including the Precision Medicine Initiative and the Cancer Moonshot, new criminal justice reforms including the Data-Driven Justice and Police Data Initiatives that cover more than 94 million Americans, as well as leading the national data efforts. He also has been active in national security and for his efforts was awarded by Secretary Carter the Department of Defense Medal for Distinguished Public Service, which is the highest honor the department bestows on a civilian.
In industry, he led the product teams at RelateIQ which was acquired by Salesforce, and was founding board member for Crisis Text Line, which works to use new technologies to provide on demand mental and crisis support. He was also Chief Scientist, Chief Security Officer and Head of Analytics and Data Product Teams at the LinkedIn Corporation where he co-coined the term Data Scientist. He has also held a number of roles at Skype, PayPal, and eBay.
As a member of the faculty at the University of Maryland, his research focused on nonlinear dynamics and chaos theory and he helped start a major research initiative on numerical weather prediction. As an AAAS Science & Technology Policy Fellow for the Department of Defense, Dr. Patil directed new efforts to leverage social network analysis and the melding of computational and social sciences to anticipate emerging threats to the US. He has also co-chaired a major review of US efforts to prevent bioweapons proliferation in Central Asia and co-founded the Iraqi Virtual Science Library (IVSL). In 2104 he was selected by the World Economic Forum as a Young Global Leader and is also a Member of the Council of Foreign Relations.